Comparing investments with long lead-times can be an exercise in futility. Trying to obtain credible inputs for outcomes 15 to 20 years hence is fraught with challenges and conventional methodology, such as modeling net present value, is of limited effectiveness. As a result, portfolio decisions—in industries from genomics to technology to energy—often skew toward low-risk choices, effectively cutting off the innovative pipeline necessary to achieve corporate growth.
Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren
A more-effective approach has emerged that can guide decision making for early stage, long-term investments. In this webinar, we demonstrate an approach that starts with corporate objectives and combines multi-attribute utility theory and value-focused thinking to create new and better distinctions for decision making. By separating discussions of preferences and corporate objectives from the scientific evaluation of individual project opportunities, decision teams can better evaluate investments—even those that are decades away from results.
Using an example from the pharmaceutical industry, we will demonstrate the benefit of this approach for early-stage portfolio decisions.
View this webinar to learn:
Speakers
Webinars
Explore further insights from our experts by checking out our webinars.
- Webinar
Toward Superforecasting®: Lessons from the Eli Lilly Probability Assessment Panel
- Webinar
The Importance of Portfolio Strategy in an Era of Real-Time Portfolio Management
- Webinar